Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18137164 | 0.94 | GLS (0.89) | GLSALDH1A1MAPTNPSR1 | |
| SCHEMBL14987538 | 0.91 | GLS (1.00) | GLS | |
| SCHEMBL21369059 | 0.90 | GLS (0.81) | GLSALDH1A1MAPTNPSR1 | |
| SCHEMBL14987545 | 0.85 | GLS (1.00) | GLSALDH1A1MAPT | |
| SCHEMBL14987277 | 0.85 | GLS (1.00) | GLSALDH1A1MAPT | |
| SCHEMBL14987416 | 0.82 | GLS (1.00) | GLSALDH1A1MAPT | |
| SCHEMBL22031630 | 0.81 | GLS (0.79) | GLS | |
| SCHEMBL21369062 | 0.76 | GLS (0.81) | GLSALDH1A1MAPT | |
| SCHEMBL14987539 | 0.76 | GLS (1.00) | GLS | |
| SCHEMBL14987168 | 0.76 | GLS (1.00) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277276-B1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| US-10441587-B2 | Treatment of lung cancer with inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2018039442-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | LIANG YU (US) | 2018-03-01 | — | — | US | disclosed |
| WO-2016160980-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287585-A1 | Treatment of Lung Cancer with Inhibitors of Glutaminase | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20150258082-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2015-09-17 | — | — | US | disclosed |
| WO-2015138902-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014089048-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885MAPT 3123/4885 |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885MAPT 3123/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885MAPT 3123/4885 |
| US-10441587-B2 | Treatment of lung cancer with inhibitors of glutaminase | KRAS, GLS, GLUL | GLS 2/4885ALDH1A1 885/4885MAPT 4458/4885 |
| US-20160287585-A1 | Treatment of Lung Cancer with Inhibitors of Glutaminase | KRAS, GLS, GLUL | GLS 2/4885ALDH1A1 885/4885MAPT 4458/4885 |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885MAPT 3123/4885 |
| US-20180055825-A1 | TREATMENT OF CANCER WITH INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 293/4885MAPT 3759/4885 |
| US-20160287564-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 1051/4885MAPT 3514/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 263/4885MAPT 4290/4885 |
| US-20150258082-A1 | COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS | GLS, GLUL, GLS2 | GLS 1/4885ALDH1A1 704/4885MAPT 4563/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885ALDH1A1 639/4885MAPT 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.